Technical Analysis for EMMA - Emmaus Life Sciences, Inc.

Grade Last Price % Change Price Change
grade B 3.37 0.00% 0.00
EMMA closed unchanged on Wednesday, August 21, 2019, on 19 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical EMMA trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
New Downtrend Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%

Older signals for EMMA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Medicine Health Medical Specialties Pharmaceutical Medication Therapeutic Products Sickle Cell Disease Therapeutic Rare And Orphan Diseases
Is EMMA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.8
52 Week Low 0.62
Average Volume 137,380
200-Day Moving Average 1.7579
50-Day Moving Average 2.9981
20-Day Moving Average 4.4803
10-Day Moving Average 3.529
Average True Range 0.6936
ADX 25.34
+DI 24.4351
-DI 26.7358
Chandelier Exit (Long, 3 ATRs ) 5.1692
Chandelier Exit (Short, 3 ATRs ) 4.8908
Upper Bollinger Band 6.7339
Lower Bollinger Band 2.2267
Percent B (%b) 0.25
BandWidth 100.600406
MACD Line -0.0393
MACD Signal Line 0.209
MACD Histogram -0.2483
Fundamentals Value
Market Cap 14.29 Million
Num Shares 4.24 Million
EPS -2.72
Price-to-Earnings (P/E) Ratio -1.24
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.53
Resistance 3 (R3) 3.53 3.46 3.51
Resistance 2 (R2) 3.46 3.42 3.47 3.50
Resistance 1 (R1) 3.42 3.40 3.42 3.42 3.49
Pivot Point 3.35 3.35 3.36 3.36 3.35
Support 1 (S1) 3.31 3.31 3.32 3.32 3.25
Support 2 (S2) 3.24 3.29 3.25 3.24
Support 3 (S3) 3.20 3.24 3.23
Support 4 (S4) 3.21